Cohort 1 (n=8) | Cohort 4 (n=10) | Total (n=18) | |
Age, median years (range) | 67 (27–68) | 62 (38–77) | 66 (27–77) |
Male, n (%) | 5 (62.5) | 9 (90.0) | 14 (77.8) |
Screening ECOG PS, n (%) | |||
0 | 4 (50.0) | 5 (50.0) | 9 (50.0) |
1 | 4 (50.0) | 5 (50.0) | 9 (50.0) |
Primary tumor site, n (%) | |||
Gastric | 7 (87.5) | 10 (100.0) | 17 (94.4) |
Proximal | 2 (25.0) | 2 (20.0) | 4 (22.2) |
Distal | 4 (50.0) | 5 (50.0) | 9 (50.0) |
Other | 1 (12.5) | 3 (30.0) | 4 (22.2) |
GEJ | 1 (12.5) | 0 | 1 (5.6) |
Differentiation, n (%) | |||
Well differentiated | 1 (12.5) | 1 (10.0) | 2 (11.1) |
Moderately differentiated | 1 (12.5) | 3 (30.0) | 4 (22.2) |
Poorly differentiated | 4 (50.0) | 6 (60.0) | 10 (55.6) |
Unknown | 2 (25.0) | 0 | 2 (11.1) |
Number of prior regimens | |||
1 | 0 | 2 (20.0) | 2 (11.1) |
2 | 4 (50.0) | 4 (40.0) | 8 (44.4) |
3 | 2 (25.0) | 3 (30.0) | 5 (27.8) |
4 | 2 (25.0) | 1 (10.0) | 3 (16.7) |
The safety analysis set includes patients who received at least one dose of andecaliximab.
ECOG status: 0=Fully active, able to perform all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory and able to perform light or sedentary work; and 2=Ambulatory and capable of self-care but unable to perform working activities (up and about more than 50% of waking hours)
ECOG PS, Eastern Cooperative Oncology Group performance status; GEJ, gastroesophageal junction.